VCELVericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 MediWound Q2 Earnings Call Highlights MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment. Chief Executive Officer Ofer Gone | ||
 Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […] | ||
 Vericel Q2 Earnings Call Highlights Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation. Total revenue rose 22% from a year earlier to $77.5 million, e | ||
 Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||